ACR Open Rheumatol

GLP-1 agonists show promise in reducing RA disease activity, CV risk

September 16, 2025

GLP-1 RAs may offer dual benefits for patients with rheumatoid arthritis (RA) and obesity, improving both inflammatory disease activity and cardiometabolic risk. Findings support further investigation into GLP-1 RAs as adjunctive therapy in RA management, particularly for patients with metabolic comorbidities.

Study details: This retrospective chart review evaluated 215 patients with RA and BMI ≥27 who were prescribed semaglutide or tirzepatide between 2018 and 2024. Of these, 173 patients initiated treatment and 42 didn't. Patients were followed for up to one year, with assessments every three months. Outcomes included RA disease activity, CV risk markers, and patient-reported measures.

Results: GLP-1 RA–treated patients showed significantly greater improvements in RA disease activity, pain, weight, total cholesterol, and HbA1c compared with controls (P < 0.05). Within the treatment group, inflammatory markers (ESR, CRP) and lipid parameters (LDL, triglycerides) also improved significantly. However, nearly one third of the treatment group discontinued therapy, most commonly due to GI side effects.

Source:

Kellner DA, et al. (2025, September 7). ACR Open Rheumatol. Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis. https://pubmed.ncbi.nlm.nih.gov/40932015/